Business Context and Reporting Period
Company: Actuate Therapeutics, Inc. (ACTU)
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2026
Reporting Period: Event date July 15, 2026; Non-compliance period June 1, 2026 to July 14, 2026.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the Market Value of Listed Securities (MVLS).
- Market Value of Listed Securities (MVLS): Below the $50 million minimum requirement for continued listing on The Nasdaq Global Market during the period of June 1, 2026, through July 14, 2026.
Material Changes
The Company received a formal Notice from Nasdaq on July 15, 2026, stating that its MVLS failed to meet the $50 million threshold required by Nasdaq Listing Rule 5450(b)(2)(A) for the preceding 44-day period. This represents a material change in the Company's listing status, triggering a compliance period.
Guidance, Outlook, and Risks
Compliance Timeline: The Company has 180 calendar days from the date of the Notice, until January 11, 2027, to regain compliance. Compliance is achieved if the MVLS closes at $50 million or more for a minimum of ten consecutive business days during this period.
Management Commentary: The Company intends to actively monitor its MVLS and take all reasonable measures to regain compliance. The Notice has no immediate effect on trading; the stock continues to trade under the symbol "ACTU."
Risks and Contingencies:
- If the Company fails to regain compliance by January 11, 2027, Nasdaq will issue a delisting notice.
- The Company may appeal a delisting determination, though success is not assured.
- Alternatively, the Company may consider transferring its listing to The Nasdaq Capital Market.
- There is no assurance the Company will be able to regain or maintain compliance with listing standards.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess progress toward the $50 million threshold.
- Monitor the stock price for ten consecutive business days to determine if the compliance requirement is met before the January 11, 2027 deadline.
- Review the Company's Annual Report on Form 10-K for the year ended December 31, 2025, for detailed risk factors.
- Watch for future 8-K filings regarding potential appeals or transfer applications to The Nasdaq Capital Market if compliance is not achieved.